Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole

Journal of Clinical Pharmacology

Volumn 50, Issue 3, 2010, Pages 320-330

  Sugimoto, Mitsushige ^a   Nishino, Masafumi ^a   Kodaira, Chise ^a   Yamade, Mihoko ^a   Ikuma, Mutsuhiro ^a   Tanaka, Tatsuo ^a   Sugimura, Haruhiko ^a   Hishida, Akira ^a   Furuta, Takahisa ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aspirin; CYP2C19; Gastroesophageal reflux disease; Nonsteroidal anti inflammatory drugs; Rabeprazole

Indexed keywords

ACETYLSALICYLIC ACID; CYTOCHROME P450 2C19; PLACEBO; RABEPRAZOLE;

ADULT; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; ENDOSCOPY; ESOPHAGUS INJURY; ESOPHAGUS MUCOSA; FEMALE; GASTRIC PH MONITORING; GASTROESOPHAGEAL REFLUX; HUMAN; MALE; STOMACH ACID SECRETION; VASODILATATION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; ASPIRIN; CROSS-OVER STUDIES; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ESOPHAGEAL PH MONITORING; ESOPHAGITIS, PEPTIC; ESOPHAGOSCOPY; FEMALE; GASTRIC MUCOSA; GASTROESOPHAGEAL REFLUX; GENOTYPE; HEARTBURN; HUMANS; JAPAN; MALE; MUTATION; PLATELET AGGREGATION INHIBITORS; YOUNG ADULT;

EID: 77649207168     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009344983     Document Type: Article

References (48)

1. Nasseri-Moghaddam S., Mofid A., Ghotbi MH, et al. Epidemiological study of gastro-oesophageal reflux disease: reflux in spouse as a risk factor. Aliment Pharmacol Ther. 2008 ; 28: 144-153.
2. Boeckxstaens GE The pathophysiology of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2007 ; 26: 149-160.
3. Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol. 2007 ; 41: 131-137.
4. Nagahara A., Miwa H., Minoo T., et al. Increased esophageal sensitivity to acid and saline in patients with nonerosive gastroesophageal reflux disease. J Clin Gastroenterol. 2006 ; 40: 891-895.
5. Miwa H., Sasaki M., Furuta T., et al. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Aliment Pharmacol Ther. 2007 ; 26: 69-77.
6. Joh T., Miwa H., Higuchi K., et al. Validity of endoscopic classification of nonerosive reflux disease. J Gastroenterol. 2007 ; 42: 444-449.
7. Wilkins WE, Ridley MG, Pozniak AL Benign stricture of the oesophagus: role of non-steroidal anti-inflammatory drugs. Gut. 1984 ; 25: 478-480.
8. El-Serag HB, Sonnenberg A. Association of esophagitis and esophageal strictures with diseases treated with nonsteroidal anti-inflammatory drugs. Am J Gastroenterol. 1997 ; 92: 52-56.
9. Ryan P., Hetzel DJ, Shearman DJ, et al. Risk factors for ulcerative reflux oesophagitis: a case-control study. J Gastroenterol Hepatol. 1995 ; 10: 306-312.
10. Lanas A., Hirschowitz BI Significant role of aspirin use in patients with esophagitis. J Clin Gastroenterol. 1991 ; 13: 622-627.
11. Diaz-Rubio M., Moreno-Elola-Olaso C., Rey E., et al. Symptoms of gastro-oesophageal reflux: prevalence, severity, duration and associated factors in a Spanish population. Aliment Pharmacol Ther. 2004 ; 19: 95-105.
12. Kotzan J., Wade W., Yu HH Assessing NSAID prescription use as a predisposing factor for gastroesophageal reflux disease in a Medicaid population. Pharm Res. 2001 ; 18: 1367-1372.
13. Hernandez-Diaz S., Rodriguez LA Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2 000; 160: 2093-2099.
14. Derry S., Loke YK Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000 ; 321: 1183-1187. 15.
15. Weil J., Colin-Jones D., Langman M., et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995 ; 310: 827-830.
16. Lanza FL, Royer GL Jr, Nelson RS Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med. 1980 ; 303: 136-138.
17. Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 1996 ; 348: 1413-1416.
18. Sorensen HT, Mellemkjaer L., Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000 ; 95: 2218-2224.
19. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med. 1994 ; 121: 161-167.
20. Bell NJ, Burget D., Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion. 1992 ; 51 (suppl 1). 59-67.
21. Shirai N., Furuta T., Moriyama Y., et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther. 2001 ; 15: 1929-1937. (Pubitemid 34014349)
22. Furuta T., Ohashi K., Kosuge K., et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther. 1999 ; 65: 552-561.
23. Sugimoto M., Furuta T., Shirai N., et al. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther. 2004 ; 76: 290-301.
24. Furuta T., Shirai N., Watanabe F., et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther. 2002 ; 72: 453-460.
25. Ishizaki T., Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther. 1999 ; 13 (suppl 3). 27-36.
26. Yasuda S., Horai Y., Tomono Y., et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4?-hydroxylation status. Clin Pharmacol Ther. 1995 ; 58: 143-154.
27. Adachi K., Katsube T., Kawamura A., et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther. 2000 ; 14: 1259-1266.
28. Miki K., Ichinose M., Ishikawa KB, et al. Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. Jpn J Cancer Res. 1993 ; 84: 1086-1090.
29. Sugimoto M., Furuta T., Shirai N., et al. Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther. 2006 ; 80: 539-548.
30. Sugimoto M., Furuta T., Shirai N., et al. Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes. Clin Pharmacol Ther. 2005 ; 77: 302-311.
31. Armstrong D., Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology. 1996 ; 111: 85-92.
32. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996 ; 20: 1161-1181.
33. de Morais SM, Goldstein JA, Xie HG, et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther. 1995 ; 58: 404-411.
34. de Morais SM, Wilkinson GR, Blaisdell J., et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994 ; 46: 594-598.
35. Savarino V., Mela GS, Zentilin P., et al. Effect of one-month treatment with nonsteroidal antiinflammatory drugs (NSAIDs) on gastric pH of rheumatoid arthritis patients. Dig Dis Sci. 1998 ; 43: 459-463.
36. Avidan B., Sonnenberg A., Schnell TG, et al. Risk factors for erosive reflux esophagitis: a case-control study. Am J Gastroenterol. 2001 ; 96: 41-46.
37. Avidan B., Sonnenberg A., Schnell TG, et al. Risk factors of oesophagitis in arthritic patients. Eur J Gastroenterol Hepatol. 2001 ; 13: 1095-1099.
38. Ruszniewski P., Soufflet C., Barthelerny P., et al. NSAIDs intake is a risk factor for gastroesophageal reflux Gastroenterology. 2007 ;132(suppl 2): M1917.
39. Laine L., Bombardier C., Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology. 2002 ; 123: 1006-1012.
40. Laine L., Maller E., Yu C., et al. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology. 2004 ; 127: 395-402.
41. Orland R. Oesophageal mucosal resistance. Aliment Pharmacol Ther. 1998 ; 12: 191-197.
42. Semble EL, Wu WC, Castell DO Nonsteroidal antiinflammatory drugs and esophageal injury. Semin Arthritis Rheum. 1989 ; 19: 99-109.
43. Poplawski C., Sosnowski D., Szaflarska-Poplawska A., et al. Role of bile acids, prostaglandins and COX inhibitors in chronic esophagitis in a mouse model. World J Gastroenterol. 2006 ; 12: 1739-1742.
44. Triadafilopouloa G., Kaur B., Sood S., et al. The effects of esomeprazole combined with aspirin or rofecoxib on prostaglandin E2 production in patients with Barrett?s oesophagus. Aliment Pharmacol Ther. 2006 ; 23: 997-1005.
45. Yasue H., Ogawa H., Tanaka H., et al. Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Japanese Antiplatelets Myocardial Infarction Study (JAMIS) Investigators. Am J Cardiol. 1999 ; 83: 1308-1313.
46. Hongo M., Traube M., McAllister RG Jr, et al. Effects of nifedipine on esophageal motor function in humans: correlation with plasma nifedipine concentration. Gastroenterology. 1984 ; 86: 8-12. (Pubitemid 14177312)
47. Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 2005 ; 352: 238-244.
48. Chan FK, Graham DY Review article: prevention of nonsteroidal anti-inflammatory drug gastrointestinal complications- review and recommendations based on risk assessment. Aliment Pharmacol Ther 2004 ; 19: 1051-1061.